Proposed Collection; Comment Request; NCI Cancer Information Service Base Demographics/Customer Service Data Collection, 54503-54504 [E6-15296]
Download as PDF
<![CDATA[
54503
Federal Register / Vol. 71, No. 179 / Friday, September 15, 2006 / Notices
Lake Success, New York, Court of
Federal Claims Number 06–0481V.
61. Angelena and Joseph Gonzales on
behalf of Tomas Russell Gonzales,
Deceased, Shiprock, New Mexico, Court
of Federal Claims Number 06–0487V.
62. Jimmie Lee Lazenberry,
Jacksonville, Florida, Court of Federal
Claims Number 06–0493V.
Dated: September 6, 2006.
Elizabeth M. Duke,
Administrator.
[FR Doc. E6–15287 Filed 9–14–06; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; NCI Cancer Information
Service Base Demographics/Customer
Service Data Collection
SUMMARY: In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Cancer Institute (NCI), the
National Institutes of Health (NIH) will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Proposed Collection: Title: NCI Cancer
Information Service Base
Demographics/Customer Service Data
Collection. Type of Information
Collection Request: Revision of
currently approved collection 0925–
0208. Need and Use of Information
Collection: The National Cancer
Institute’s Cancer Information Service
(CIS) provides the latest information on
cancer, clinical trials, and tobacco
cessation. Characterizing clients and
how they found out about the CIS is
essential to customer service, program
planning and promotion. This effort
involves a brief survey of clients of the
1–800–4–CANCER and 1–877–44U–
QUIT toll-free services and LiveHelp, a
web-based chat service. The telephone
survey contains eight questions—3
customer service and 5 demographic—
asked of a subset of callers (cancer
patients, tobacco users, their family or
friends, and the general public) at the
end of usual service for an annual total
of approximately 115,944 callers. All
(100%) of these telephone clients will
Estimated
number of responses per
respondent
Estimated
number of
respondents
Type of respondents
be asked the 3 customer service
questions for an annual total of 113,061
callers. Of the 113,061 telephone clients
we serve annually, 36% (n=40,702) will
be randomly selected and asked five
additional demographic questions. The
LiveHelp web survey involves 50% of
LiveHelp clients the same eight
questions (3 customer service questions
and 5 demographic questions) for an
annual total of approximately 2,883
users. The combined total of clients to
be surveyed each year for both
telephone and LiveHelp services is
115,944 for a total of annual burden
hours of 2,616. Frequency of Response:
Single time. Affected Public: Individuals
or households. Type of Respondents:
Patients, relatives, friends, and general
public. The annual reporting burden is
as follows:
Estimated Number of Respondents:
115,944; Estimated Number of
Responses per Respondent: 1; Average
Burden Hours Per Response: 0.0167 and
Estimated Total Annual Burden Hours
Requested: 2616. The annualized cost to
respondents is estimated at: $47,323.
There are no Capital Costs to report.
There are no Operating or Maintenance
Costs to report.
Average burden hours per
response
Estimated total
annual burden
hours requested
Telephone Client 1
5 Demographic Questions (average annual sampling rate = 36%) .........
3 Customer Service (100% sampling) ..................................................
LiveHelp Clients 2
5 Demographic + 3 Customer Service questions (50% sampling) ..........
40,702
113,061
1
1
0.0167
0.0167
680
1888
2883
1
0.0167
48
Total ...................................................................................................
115,944
........................
........................
2,616
jlentini on PROD1PC65 with NOTICES
1 Approximately 36% of telephone and quitline clients will be sampled for the demographic questions. That is, 25% will be routinely sampled
and up to 100% will be sampled for short periods of time during special promotions. This will average to be about 36% of all callers annually.
The 40,702 clients who are asked the 5 demographic questions are not additional clients as they are included in the 113,061 who answer the 3
customer service questions. However, they do have additional burden as they are asked the 5 the additional demographic questions. Thus, a
burden calculation for these additional 5 questions is presented and the total number of respondents is equal to 113,061 for telephone clients
plus 2,883 for LiveHelp clients.
2 Approximately 50% of LiveHelp clients will be sampled for demographic and customer service questions.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
VerDate Aug<31>2005
14:51 Sep 14, 2006
Jkt 208001
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
FOR FURTHER INFORMATION CONTACT:
Written comments and/or suggestions
regarding the item(s) contained in this
notice, especially regarding the
estimated public burden and associated
response time, should be directed to the:
Office of Management and Budget,
Office of Regulatory Affairs, New
Executive Office Building, Room 10235,
Washington, DC 20503, Attention: Desk
Officer for NIH. To request more
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact Linda
Squiers, Ph.D., Project Officer, National
Cancer Institute, Cancer Information
Service, 6116 Executive Blvd., Suite
3056A, Room 3029, Rockville, MD
20892 or call non-toll-free number 301–
594–9075 or E-mail your request,
including your address to:
squiersl@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
E:\FR\FM\15SEN1.SGM
15SEN1
54504
Federal Register / Vol. 71, No. 179 / Friday, September 15, 2006 / Notices
Dated: September 7, 2006.
Rachelle Ragland-Greene,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. E6–15296 Filed 9–14–06; 8:45 am]
BILLING CODE 4101–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
jlentini on PROD1PC65 with NOTICES
Human Protein Tissue Inhibitor of
Metalloproteinases-2 (TIMP–2) Derived
Anti-Angiogenic Peptides
Description of Technology: Cancer is
the second leading cause of death in
United States and it is estimated that
there will be approximately 600,000
deaths caused by cancer in 2006. A
major drawback of the existing
chemotherapies is the cytotoxic sideeffects that are associated with them.
Thus, there is a need to develop new
therapeutic approaches with reduced
side-effects.
Anti-angiogenic therapy is a recent
approach in cancer therapeutics
targeting the formation of blood vessels
that are necessary for tumor growth.
Recently, the anti-angiogenic molecule
bevacizumab (Avastin) has gained
approval from the FDA for the first-line
treatment of metastatic colon cancer in
combination with standard
chemotherapy.
VerDate Aug<31>2005
14:51 Sep 14, 2006
Jkt 208001
Human protein tissue inhibitor of
metalloproteinases-2 (TIMP–2) has been
shown to inhibit angiogenesis in vivo
independent of metalloproteinase
inhibition. This technology discloses
new peptide sequences derived from
TIMP–2. They retain their in vivo antiangiogenic property acting via the same
mechanism as TIMP–2 and some of
them have significantly higher activity
than TIMP–2. Anti-angiogenic
peptidomimetics based on this
technology can be developed for the
treatment of angiogenesis associated
diseases.
Applications:
1. Novel human TIMP–2 derived
peptide sequences.
2. Novel human TIMP–2 derived
peptide sequences with considerable
anti-angiogenic activity in vivo.
3. Human TIMP–2 derived peptides
with high anti-angiogenic activity that
can be used for the treatment of several
cancers.
4. Human TIMP–2 derived peptides
with high anti-angiogenic activity that
can be used for the treatment of several
other angiogenesis associated diseases
such as retinopathy and rheumatoid
arthritis.
Market:
1. 600,000 deaths from cancer related
diseases estimated in 2006.
2. The technology platform involving
novel anti-angiogenic cancer therapy
technology has a potential market of
more than 2 billion U.S. dollars.
3. The technology platform has
additional market in treating several
other clinical problems such as
autoimmune diseases.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: William G. StetlerStevenson and Dong-Wan Seo (NCI)
(Lead Inventor Web page: https://
ccr.cancer.gov/staff/
staff.asp?profileid=5853)
Related Publications:
1. DW Seo, et al. TIMP–2 mediated
inhibition of angiogenesis: an MMPindependent mechanism. Cell 2003 Jul
25; 114(2):171–180.
2. WG Stetler-Stevenson, et al. Tissue
inhibitor of metalloproteinases-2
(TIMP–2) mRNA expression in tumor
cell lines and human tumor tissues. J
Biol Chem. 1990 Aug 15;
265(23):13933–13938.
3. WG Stetler-Stevenson and DW Seo.
TIMP–2: an endogenous inhibitor of
angiogenesis. Trends Mol Med. 2005
Mar; 11(3):97–103.
4. DW Seo, et al. Shp-1 mediates the
antiproliferative activity of tissue
inhibitor of metalloproteinase-2 in
human microvascular endothelial cells.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
J Biol Chem. 2006 Feb 10; 281(6):3711–
3721.
5. H Chang, et al. TIMP–2 promotes
cell spreading and adhesion via
upregulation of RAP1 signaling.
Biochem. Biophys. Res. Comm. 2006 Jul
7; 345(3):1201–1206.
6. J Oh, et al. TIMP–2 upregulates
RECK expression via dephosphorylation
of paxillin tyrosine residues 31 and 118.
Oncogene 2006 Jul 13; 25(30):4230–
4234.
Patent Status: U.S. Provisional
Application No. 60/728,146 filed 18 Oct
2005, entitled ‘‘Angio-inhibitory
Peptides Derived from TIMP–2’’ (HHS
Reference No. E–186–2005/0–US–01).
Licensing Status: Available for
exclusive and non-exclusive licensing.
Licensing Contact: Thomas P. Clouse,
J.D.; 301/435–4076;
clousetp@mail.nih.gov.
Collaborative Research Opportunity:
The NCI Cell and Cancer Biology
Branch is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize TIMP–2 derived antiangiogenic peptides. Please contact
Betty Tong at 301–496–0477 or
tongb@mail.nih.gov for more
information.
Novel Chemoattractant-Based Toxins
To Improve Vaccine Immune
Responses for Cancer and Infectious
Diseases
Description of Technology: Cancer is
one of the leading causes of death in
United States and it is estimated that
there will be more than half a million
deaths caused by cancer in 2006. A
major drawback of the current
chemotherapy-based therapeutics is the
cytotoxic side-effects associated with
them. Thus there is a dire need to
develop new therapeutic strategies with
fewer side-effects. Immuno-therapy has
taken a lead among the new therapeutic
approaches. Enhancing the innate
immune response of an individual has
been a key approach for the treatment
against different diseases such as cancer
and infectious diseases.
This technology involves the
generation of novel chemoattractant
toxins that deplete the T regulatory cells
(Treg) or other immunosuppressive or
hyperactivated cells locally. Treg
controls activation of immune responses
by suppressing the induction of
adaptive immune responses,
particularly T cell responses.
Immunosuppressive cells such as tumor
infiltrating macrophages or NKT and
other cells down regulate antitumor
immune responses. The chemoattractant
toxins consist of a toxin moiety fused
E:\FR\FM\15SEN1.SGM
15SEN1
]]>Agencies
[Federal Register Volume 71, Number 179 (Friday, September 15, 2006)]
[Notices]
[Pages 54503-54504]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-15296]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment Request; NCI Cancer Information
Service Base Demographics/Customer Service Data Collection
SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995, for opportunity for public comment
on proposed data collection projects, the National Cancer Institute
(NCI), the National Institutes of Health (NIH) will publish periodic
summaries of proposed projects to be submitted to the Office of
Management and Budget (OMB) for review and approval.
Proposed Collection: Title: NCI Cancer Information Service Base
Demographics/Customer Service Data Collection. Type of Information
Collection Request: Revision of currently approved collection 0925-
0208. Need and Use of Information Collection: The National Cancer
Institute's Cancer Information Service (CIS) provides the latest
information on cancer, clinical trials, and tobacco cessation.
Characterizing clients and how they found out about the CIS is
essential to customer service, program planning and promotion. This
effort involves a brief survey of clients of the 1-800-4-CANCER and 1-
877-44U-QUIT toll-free services and LiveHelp, a web-based chat service.
The telephone survey contains eight questions--3 customer service and 5
demographic--asked of a subset of callers (cancer patients, tobacco
users, their family or friends, and the general public) at the end of
usual service for an annual total of approximately 115,944 callers. All
(100%) of these telephone clients will be asked the 3 customer service
questions for an annual total of 113,061 callers. Of the 113,061
telephone clients we serve annually, 36% (n=40,702) will be randomly
selected and asked five additional demographic questions. The LiveHelp
web survey involves 50% of LiveHelp clients the same eight questions (3
customer service questions and 5 demographic questions) for an annual
total of approximately 2,883 users. The combined total of clients to be
surveyed each year for both telephone and LiveHelp services is 115,944
for a total of annual burden hours of 2,616. Frequency of Response:
Single time. Affected Public: Individuals or households. Type of
Respondents: Patients, relatives, friends, and general public. The
annual reporting burden is as follows:
Estimated Number of Respondents: 115,944; Estimated Number of
Responses per Respondent: 1; Average Burden Hours Per Response: 0.0167
and Estimated Total Annual Burden Hours Requested: 2616. The annualized
cost to respondents is estimated at: $47,323. There are no Capital
Costs to report. There are no Operating or Maintenance Costs to report.
----------------------------------------------------------------------------------------------------------------
Estimated Estimated
Estimated number of Average burden total annual
Type of respondents number of responses per hours per burden hours
respondents respondent response requested
----------------------------------------------------------------------------------------------------------------
Telephone Client \1\
5 Demographic Questions (average annual 40,702 1 0.0167 680
sampling rate = 36%).......................
3 Customer Service (100% sampling).......... 113,061 1 0.0167 1888
LiveHelp Clients \2\
5 Demographic + 3 Customer Service questions 2883 1 0.0167 48
(50% sampling).............................
---------------------------------------------------------------
Total................................... 115,944 .............. .............. 2,616
----------------------------------------------------------------------------------------------------------------
\1\ Approximately 36% of telephone and quitline clients will be sampled for the demographic questions. That is,
25% will be routinely sampled and up to 100% will be sampled for short periods of time during special
promotions. This will average to be about 36% of all callers annually. The 40,702 clients who are asked the 5
demographic questions are not additional clients as they are included in the 113,061 who answer the 3 customer
service questions. However, they do have additional burden as they are asked the 5 the additional demographic
questions. Thus, a burden calculation for these additional 5 questions is presented and the total number of
respondents is equal to 113,061 for telephone clients plus 2,883 for LiveHelp clients.
\2\ Approximately 50% of LiveHelp clients will be sampled for demographic and customer service questions.
Request for Comments: Written comments and/or suggestions from the
public and affected agencies are invited on one or more of the
following points: (1) Whether the proposed collection of information is
necessary for the proper performance of the function of the agency,
including whether the information will have practical utility; (2) The
accuracy of the agency's estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (3) Ways to enhance the quality, utility, and
clarity of the information to be collected; and (4) Ways to minimize
the burden of the collection of information on those who are to
respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
FOR FURTHER INFORMATION CONTACT: Written comments and/or suggestions
regarding the item(s) contained in this notice, especially regarding
the estimated public burden and associated response time, should be
directed to the: Office of Management and Budget, Office of Regulatory
Affairs, New Executive Office Building, Room 10235, Washington, DC
20503, Attention: Desk Officer for NIH. To request more information on
the proposed project or to obtain a copy of the data collection plans
and instruments, contact Linda Squiers, Ph.D., Project Officer,
National Cancer Institute, Cancer Information Service, 6116 Executive
Blvd., Suite 3056A, Room 3029, Rockville, MD 20892 or call non-toll-
free number 301-594-9075 or E-mail your request, including your address
to: squiersl@mail.nih.gov.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 60 days
of the date of this publication.
[[Page 54504]]
Dated: September 7, 2006.
Rachelle Ragland-Greene,
NCI Project Clearance Liaison, National Institutes of Health.
[FR Doc. E6-15296 Filed 9-14-06; 8:45 am]
BILLING CODE 4101-01-P
